Dr. Charles Reay Mackay To Join Pfizer as Chief Scientific Officer, Inflammation and Immunology Research Unit
March 30 2015 - 11:00AM
Business Wire
Pfizer Inc. announced today that Charles Reay Mackay, Ph.D.,
will join the company as Chief Scientific Officer for Pfizer’s
Inflammation and Immunology Research Unit. Professor Mackay will
report directly to José-Carlos Gutiérrez-Ramos, Ph.D., group vice
president of BioTherapeutics Research & Development, and will
be based in Pfizer’s R&D hub in Cambridge, MA.
“Professor Mackay’s research has focused on understanding the
fundamental mechanisms that regulate the immune system, developing
new monoclonal antibody treatments for inflammation and exploring
strategies to prevent inflammatory diseases through gut
microbe/epithelial barrier modulation,” said Dr. Gutiérrez-Ramos.
“Professor Mackay brings to Pfizer a unique combination of
scientific expertise, academic credentials and entrepreneurial
spirit. His deep commitment to drug discovery and
his unique skill set will help advance Pfizer’s position as a
global leader in inflammation and a collaborator of choice within
the Cambridge community and beyond.”
Professor Mackay will join Pfizer from Monash University in
Australia, where he is a research fellow, and the Charles Perkins
Center within the Faculty of Medicine at Sydney University, where
he was Chair of Diabetes. Professor Mackay has also held important
biotech leadership positions at LeukoSite Inc. and Millennium
Therapeutics in Cambridge, Massachusetts. He has authored more than
160 peer-reviewed scientific publications and is a member of the
Australian Academy of Science and was an Australia Fellow at the
National Health and Medical Research Council of Australia.
“I am privileged to be joining a world-class team of scientists
that has made an important contribution to the field of
Inflammation and Immunology research,” said Professor Mackay. “We
have an important opportunity to advance a robust pipeline of novel
agents that target the root cause of inflammation at a molecular
level across several disease areas such as inflammatory bowel
disease (IBD), lupus, psoriasis, Chronic Obstructive Pulmonary
Disorder and other chronic diseases. We will also pursue other
novel approaches that could help transform the way inflammatory
diseases are treated.”
Inflammation and Immunology is one of Pfizer’s key therapeutic
areas, where Pfizer has a unique opportunity to bring important
potential new therapies to patients in need. As of February 2015,
the Inflammation and Immunology pipeline includes 19 programs from
Phase 1 through Registration.
Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products. Our global portfolio includes medicines and vaccines as
well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and
emerging markets to advance wellness, prevention, treatments and
cures that challenge the most feared diseases of our time.
Consistent with our responsibility as one of the world's premier
innovative biopharmaceutical companies, we collaborate with
healthcare providers, governments and local communities to support
and expand access to reliable, affordable healthcare around the
world. For more than 150 years, Pfizer has worked to make a
difference for all who rely on us. To learn more, please visit us
at www.pfizer.com.
DISCLOSURE NOTICE: The information contained in this
release is as of March 30, 2015. Pfizer assumes no obligation to
update forward-looking statements contained in this release as the
result of new information or future events or developments.
This release contains forward-looking information about a
Pfizer’s pipeline of inflammation and immunology agents that
involve substantial risks and uncertainties that could cause actual
results to differ materially from those expressed or implied by
such statements. Risks and uncertainties include, among other
things, the uncertainties inherent in research and development,
including, without limitation, the ability to meet anticipated
clinical trial commencement and completion dates as well as the
possibility of unfavorable clinical trial results, including
unfavorable new clinical data and additional analyses of existing
clinical data; whether and when new drug applications may be filed
in any jurisdictions for any of these pipeline products; whether
and when such applications may be approved by regulatory
authorities, which will depend on the assessment by such regulatory
authorities of the benefit-risk profile suggested by the totality
of the efficacy and safety information submitted; decisions by
regulatory authorities regarding labeling and other matters that
could affect the availability or commercial potential of any of
these pipeline products; and competitive developments.
A further description of risks and uncertainties can be found in
Pfizer's Annual Report on Form 10-K for the fiscal year ended
December 31, 2014 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned "Risk Factors" and
"Forward-Looking Information That May Affect Future Results", as
well as in its subsequent reports on Form 8-K, all of which are
filed with the SEC and available at www.sec.gov and
www.pfizer.com.
Pfizer Inc.Dean Mastrojohn, 212-733-6944
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024